Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Rivka Abulafia-Lapid"'
Autor:
Dimitrios Karussis, Hagai Shor, Julia Yachnin, Naama Lanxner, Merav Amiel, Keren Baruch, Yael Keren-Zur, Ofra Haviv, Massimo Filippi, Panayiota Petrou, Shalom Hajag, Urania Vourka-Karussis, Adi Vaknin-Dembinsky, Salim Khoury, Oded Abramsky, Henri Atlan, Irun R Cohen, Rivka Abulafia-Lapid
Publikováno v:
PLoS ONE, Vol 7, Iss 12, p e50478 (2012)
T-cell vaccination (TCV) for multiple sclerosis (MS) refers to treatment with autologous anti-myelin T-cells, attenuated by irradiation. Previously published clinical trials have been all open-labeled.To evaluate the safety and efficacy of TCV in pro
Externí odkaz:
https://doaj.org/article/f9c593252a4541e598392ac03d903842
Autor:
Aldar S. Bourinbaiar, Rivka Abulafia-Lapid, Nian-Qing Lu, Dmytro S. Silin, Vichai Jirathitikal
Publikováno v:
Current Immunology Reviews. 3:101-107
It may appear that problems of reproductive immunology have little in common with issues of treatment and prevention of AIDS. However, the certain aspects of HIV immunopathogenesis are closely related to problems faced by reproductive immunologists.
Publikováno v:
Vaccine. 25:3192-3199
We studied HIV-positive and -negative subjects for T-cell reactivity to rCD4, and found that 80% of 25 tested HIV-infected patients and 25% of controls manifested T-cell proliferation responses to rCD4. We mapped the major CD4 immunogenic epitopes am
Publikováno v:
Journal of Autoimmunity. 20:313-321
We studied T-cell proliferative responses (stimulation index: SI) and autoantibodies to human HSP60, HSP70 and HSP90 proteins in 25 children (mean age 10.1+/-3.8 years) newly diagnosed with Type 1 diabetes. The control group for T cells included 25 a
Autor:
Massimo Filippi, U. Vourka-Karussis, Panayiota Petrou, Keren Baruch, Julia Yachnin, Hagai Shor, Ofra Haviv, Adi Vaknin-Dembinsky, Rivka Abulafia-Lapid, Naama Lanxner, Henri Atlan, Dimitrios Karussis, Irun R. Cohen, Merav Amiel, Yael Keren-Zur, Shalom Hajag, Salim T. Khoury, Oded Abramsky
Publikováno v:
PLoS ONE, Vol 7, Iss 12, p e50478 (2012)
PLoS ONE
PLoS ONE
Background T-cell vaccination (TCV) for multiple sclerosis (MS) refers to treatment with autologous anti-myelin T-cells, attenuated by irradiation. Previously published clinical trials have been all open-labeled. Aim To evaluate the safety and effica
T-cell vaccination (TCV) is a unique approach to induce immune regulation that may have importance in the treatment of autoimmune diseases, including multiple sclerosis (MS). TCV employs a classic vaccine strategy of injecting an attenuated form of t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8a6fd5b9db3fbfc096bb66eadec3bb7
https://europepmc.org/articles/PMC2646469/
https://europepmc.org/articles/PMC2646469/
Publikováno v:
Expert review of vaccines. 4(3)
Recently, there has been a renewed interest in therapeutic vaccination as an adjunct or alternative to current treatment options for HIV. The first immunotherapeutic trial relevant to this topic was published in 1983. Since then, several dozen therap
Autor:
Henri Atlan, Shlomo Mayan, Irun R. Cohen, Zvi Bentwich, Yael Keren-Zur, Rivka Abulafia-Lapid, Yulia Avbramovitz
Publikováno v:
Vaccine. 23(17-18)
This study is an extended clinical trial of the one initiated and reported in the Journal of Clinical Virology 2004;31S:S48-54. Thirteen HIV-1 patients (eight subtype B and five subtype C) that manifested T-cell autoimmunity to recombinant human CD4
Publikováno v:
Autoimmunity reviews. 4(6)
The nature of clinical and physiological manifestations associated with HIV infection suggests that AIDS is an autoimmune disease. The conventional immunotherapeutic approaches aimed at enhancing the immune response against HIV have repeatedly failed
Publikováno v:
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 31
Background: Highly active antiretroviral therapy (HAART) is frequently associated with only partial restoration of CD4 T-cell levels. Autoimmunity to CD4 T-cells may account for the persistence of the CD4 T-cell lymphopenia in such cases. Objective: